Breaking News

Retatrutide is not approved in the UK, but fake pens carrying its name are turning up in large numbers. What the MHRA found in Birmingham, why it matters and how to avoid unsafe sellers.

A new once-weekly weight-loss injection works differently from Wegovy and Mounjaro. Its full Phase 2 results have now been published, and the side-effect numbers are attracting attention.

The full TRIUMPH-2 paper adds responder rates, a more cautious 18.8% analysis, blood sugar and blood pressure results and new safety detail to the 20.8% figure Lilly first announced in July.

A new name is starting to appear in weight loss medication communities across the UK. People who have recently discovered Cagrilintide are now asking questions about Eloralintide and what sets the two apart. Here is what the science actually says and what we genuinely do not know yet.

Eli Lilly has confirmed a formal early access programme for retatrutide in the United States, but the criteria are deliberately strict and the programme does not currently apply to UK patients. Here is what this announcement actually means, why it matters alongside this week's grey market safety warnings, and what anyone in the UK should understand before drawing conclusions.

Eli Lilly has announced positive Phase 3 trial results for retatrutide, and online communities are buzzing with questions about what this means for UK access. People who have been following this medication closely want honest answers about timelines, the cardiovascular safety data, and what licensed availability in the UK realistically looks like now.

An FDA advisory panel vote on several peptides is generating significant discussion in UK communities right now. People want to know what this actually means for access, legitimacy and the future of these compounds here. The answer is complicated, and most media coverage is getting key parts of it wrong.

A new study is warning that older adults on GLP-1 weight loss medicines may face hidden risks beyond the number on the scales. Losing muscle and developing frailty are serious concerns that deserve attention alongside the very real benefits of these treatments. Here is what UK patients should understand and what they can do about it.

A major new review of 262 clinical trials has ranked 19 obesity medicines by weight loss and cardiovascular benefit. The results reveal a striking gap between which drug slims you fastest and which drug may keep you alive longer. Here is what UK patients need to understand.

Counterfeit Wegovy pills have appeared on unregulated websites almost immediately after the tablet form launched in UK pharmacies. Regulators and pharmacists are urging patients to check carefully before buying. Here is what UK patients need to know to stay safe.